Jitakshi De, President & CEO
Dr. De is a Physician Scientist / Pathologist and Entrepreneur, Founder, President, and Chief Executive Officer of Deepath Medical Diagnostics, Inc. She holds a Bachelors in Biology with Highest Honors from UNC - Chapel Hill, and earned her M.D. from Duke University School of Medicine. Dr. De completed her residency in Anatomic and Clinical Pathology from University of Texas at Houston (2003 – 2007) and a fellowship in Hematopathology from University of Michigan Health System (2008 – 2009). She has a Masters in Legal Studies in Healthcare Law (M.L.S., 08/2017 - 12/2018) online from University of Oklahoma. She brings valuable industry experience in cytometry technologies, high dimensional data analysis, and cell-based disease biomarkers, with a particular focus in hematologic and oncologic disorders. She is a Fellow of the American Society of Clinical Pathology (ASCP) and the College of American Pathologists, and a recipient of ASCP's "Forty under 40" pathologists and laboratory professionals in 2014. Her research spans from genotypic-phenotypic correlations to stem cell biology and detection of leukemic stem/progenitor cells, and applications of high dimensional single cell analysis technologies.
Ramani Aiyer, Chief Business Officer
Ramani Aiyer offers strategic advisory and business development consultancy services to Life Science companies. He has >20 years of experience in the biopharmaceutical and clinical diagnostics industries, with major roles in R&D strategic planning, while mentoring scientists and leading diverse project teams. He holds a PhD in Biochemistry from Harvard, and has post-doctoral research experience from Stanford and Dana Farber Cancer Institute. He received his MBA from University of California, Berkeley Haas School of Management. Earlier, he was the Chief Scientific Officer at Actis Biologics, and prior to that, Senior VP, R&D Strategic Planning at Piramal Life Sciences. His other roles include senior level positions at Genentech, TransMed Biotech, LifeScan (acquired by Johnson & Johnson), and Sugen (acquired by Pharmacia/Pfizer).
To be announced, Chief Technology Officer
Paul H. Kane, Lead Algorithm Engineer
Paul Kane has an extensive background in signal processing and analysis of biomedical data acquired by sophisticated technologies including magnetic resonance spectroscopy and mass spectrometry. His expertise is in continuous problem solving through the application of advanced techniques combining signal and data processing, image analysis, and analytical mechanics. He applies intuition and a solid background in engineering and physics fundamentals for pattern classification of high dimensional cytometry data.
Christian T. Ballentine, Director, Operations
CT is a sound engineer and a recording artist who brings his creative insights into the operations while supporting cloud-based cytometry data analytics and social media-based marketing.